SCHEMBL6969894

SCHEMBL6969894

Oc1cccc(-c2[c]cccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 14/20 0.50
HSD17B2 P37059 13/20 0.50
CYP3A4 P08684 3/20 0.50
CYP2C9 P11712 2/20 0.50
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP2C19 P33261 1/20 0.42
CA12 O43570 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CA2 P00918 1/20 0.42
LMNA P02545 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
TNKS O95271 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6061090 0.82 HSD17B1 (0.52) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL183516 0.80 ALDH1A1 (0.35) ALDH1A1
SCHEMBL26567 0.79 MAOA (0.41) ESR1ALDH1A1
SCHEMBL589437 0.79 MAOA (0.41) ESR1ALDH1A1
SCHEMBL1411316 0.77 MMP3 (0.48) HSD17B1HSD17B2CYP3A4ESR1ESR2
SCHEMBL2115058 0.76 ACHE (0.42) CYP3A4ALDH1A1HSD17B10
SCHEMBL3298109 0.76 MAOA (0.54) CYP3A4CA12ALDH1A1CA2LMNA
SCHEMBL2115007 0.76 NPC1 (0.42) ESR2
SCHEMBL27825751 0.76 MAOB (0.43) CYP1A2ALDH1A1HSD17B10
SCHEMBL2112958 0.76 TAAR1 (0.42) HSD17B1HSD17B2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US claimed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 WO disclosed
EP-0976748-B1 PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2003-12-03 EP disclosed
EP-1064262-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS CYCLIC GMP MODULATORS IN MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-01-03 EP disclosed
US-6147100-A ANTIINFLAMMATORY AGENTS SHIONOGI & CO., LTD. (JP) 2000-11-14 US disclosed
EP-0976748-A1 PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2000-02-02 EP disclosed
WO-1999042444-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS CYCLIC GMP MODULATORS IN MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-08-26 WO disclosed